Skip to main content
Dan Felitsky

Dan Felitsky

President and CSO, Sfida Ventures
Dr. Dan Felitsky is currently President and CSO at Sfida Ventures, where he heads R&D efforts to develop novel oncology medicines. Prior to Sfida Ventures, Dan was VP of Immuno-Oncology at TigaTx, developing a novel class of IgA-based neutrophil-driven therapeutics, and head of Discovery Research at Pyxis Oncology, establishing the company’s scientific team and building through a successful IPO. He also led the Translational Science Platform at Jounce Therapeutics, originating a program partnered with Gilead for $805 million. As a scientific leader, Dan has contributed to over 40 preclinical programs, 8 INDs, and multiple clinical programs. Dan began his industry career at GlaxoSmithKline after a postdoctoral fellowship at Scripps Research. Dan holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison and a B.S. in Cell and Molecular Biology from the Pennsylvania State University.